Determining Minimal Residual Disease Using ctDNA Deep Sequencing

Recruiting now · Not applicable

Conditions studied: Esophageal Adenocarcinoma, Gastric Cancer, Pancreatic Cancer

In brief

Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment. Early identification of progression during neoadjuvant chemotherapy or diagnosis of early disease relapse during adjuvant treatment is essential to modify the treatment strategy. The aim of this project is to validate ctDNA as a biomarker of molecular relapse/progression of disease.

Key facts

Study ID

NCT07660627

Run by

Masaryk Memorial Cancer Institute

People needed

34

Starts

2022-08-22

Expected to finish

2026-12-31

Last updated by the study team

2026-06-24

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Consent to participate in the study
• Patients with esophageal, gastric, or pancreatic cancer, stage 0-2
• Patients with locally advanced, potentially operable disease treated with systemic perioperative chemotherapy or chemoradiotherapy
• Patients with metastatic disease treated with first- to third-line palliative systemic therapy

You may not qualify if…

• not specified

Where it is running

• Masaryk Memorial Cancer Institute — Brno, Czechia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.